Sodium valproate and bone marrow suppression.
Bone marrow suppression developed in a patient while she was on a regimen of sodium valproate. In addition, she had high titers of platelet autoantibodies and a coagulopathy, both recognized complications of valproate therapy. It is postulated that this drug was also responsible for the marrow suppression.
D000328:Adult; D001778:Blood Coagulation Disorders / Q000139:chemically induced; D001855:Bone Marrow Diseases / Q000139:chemically induced*; D004828:Epilepsies, Partial / Q000188:drug therapy; D005260:Female; D006801:Humans; D013921:Thrombocytopenia / Q000139:chemically induced; D014635:Valproic Acid / Q000009:adverse effects* / Q000627:therapeutic use
D014635:Valproic Acid